Royalty Pharma plc announced a $275 million synthetic royalty funding agreement with Denali Therapeutics, Inc., providing an upfront payment of $200 million at closing and an additional $75 million upon European Medicines Agency approval by December 31, 2029. The agreement grants Royalty Pharma a 9.25 % royalty on worldwide net sales of Denali’s lead investigational therapy, tividenofusp alfa, for mucopolysaccharidosis type II (Hunter syndrome).
Continue reading for full analysis...